Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | March 19, 2009 | ||||
Last Updated Date | September 27, 2012 | ||||
Start Date ICMJE | May 2009 | ||||
Estimated Primary Completion Date | March 2013 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Progression Free Survival [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00866697 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ||||
Official Title ICMJE | A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ||||
Brief Summary | This is a study to determine whether therapy with pazopanib is effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer has not progressed on first line chemotherapy. |
||||
Detailed Description | This is a randomized, two-arm, placebo controlled, double-blind, multicenter, intergroup Phase III study in women with non-bulky FIGO Stage II - IV ovarian, fallopian tube, or primary peritoneal cancer that has not progressed (i.e., CR, PR, SD) after completing their first-line chemotherapy for advanced ovarian cancer. Approximately 900 subjects will be enrolled into the study. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 3 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Estimated Enrollment ICMJE | 900 | ||||
Estimated Completion Date | December 2014 | ||||
Estimated Primary Completion Date | March 2013 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Hematologic
Or, if greater than 1.5 mg/dL: Calculated creatinine clearance at least 50 mL/min Urine Protein
Exclusion Criteria:
|
||||
Gender | Female | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States, Australia, Austria, Belgium, China, Denmark, France, Germany, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Norway, Spain, Sweden, Taiwan | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00866697 | ||||
Other Study ID Numbers ICMJE | 110655 | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | GlaxoSmithKline | ||||
Study Sponsor ICMJE | GlaxoSmithKline | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | GlaxoSmithKline | ||||
Verification Date | August 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |